Disease management
GE Research has received a grant from the NIH to develop sensors that can be embedded into mobile devices to detect COVID-19 particles on their surfaces.
Starting this month, eligible Fitbit Sense users can participate in the study, which will look into how pulse arrival time can be used to measure blood pressure.
The deal is expected to close this summer, subject to stockholder approval, and will raise $113 million for the combined company.
Although diagnostic accuracy improved, triage accuracy and anxiety levels remained unchanged from before and after the internet search.
The agency will allow some COVID-19 tests to be used at home for regular asymptomatic testing.
The startup's platform now covers more than 20 million lives and is available worldwide.
The Palo Alto startup said that 2020 was its strongest year to date.
The company currently has 11 locations delivering virtual-supported care, but now plans to open "several" more in the first half of 2021.
The startup will now move onto a larger pivotal trial of the neuromodulation therapy, which received a Breakthrough Device Designation from the FDA in January.
Providers will be able to have in-app live video conversations with chronic pain and movement disorder patients, as well as prescribe new settings for their neuromodulation therapies from afar.